A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

NCT05751928 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

411

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma Stage III
Melanoma (Skin)

Interventions

BIOLOGICAL: BCD-217
BIOLOGICAL: anti-PD1
PROCEDURE: Excision of the primary lesion
PROCEDURE: Regional lymphadenectomy

Sponsor

Biocad